The use of modeling to understand the impact of screening on US mortality: Examples from mammography and PSA testing

Eric J. Feuer, Ruth Etzioni, Kathleen A. Cronin, Angela Mariotto

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Surveillance data represent a vital resource for understanding the impact of cancer control interventions on the population cancer burden. However, population cancer trends are a complex product of many factors, and estimating the contribution of any one of these factors can be challenging. Surveillance modeling is a technique for estimating the contribution of one or more interventions of interest to trends in disease incidence and mortality. In this article, we present several approaches to surveillance modeling of cancer screening interventions. We classify models as biological or epidemiological, depending on whether they model the full unobservable aspects of disease onset and progression, or models which reduce the complex process to simpler terms by summarizing portions of the disease process using mostly observed population level measures. We also describe differences between macrolevel models, microsimulation models and mechanistic models. We discuss procedures for model calibration and validation, and methods for presenting model results which are robust with respect to certain types of biased model estimates. As examples, we present several models of the impact of mammography screening on breast cancer mortality, and PSA screening on prostate cancer mortality. Both these examples are appropriate uses of surveillance modeling, even though for mammography there is extensive (although somewhat controversial) randomized trial evidence, whereas for PSA this biomarker has seen extensive use as a screening test prior to any controlled trial evidence of its efficacy. Some of the models presented here were developed as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network.

Original languageEnglish (US)
Pages (from-to)421-442
Number of pages22
JournalStatistical methods in medical research
Volume13
Issue number6
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Mammography
Mortality
Screening
Testing
Cancer
Modeling
Surveillance
Neoplasms
Population
Biological Models
National Cancer Institute (U.S.)
Early Detection of Cancer
Model
Calibration
Disease Progression
Prostatic Neoplasms
Biomarkers
Breast Neoplasms
Incidence
Microsimulation

ASJC Scopus subject areas

  • Epidemiology
  • Nursing(all)
  • Health Information Management

Cite this

The use of modeling to understand the impact of screening on US mortality : Examples from mammography and PSA testing. / Feuer, Eric J.; Etzioni, Ruth; Cronin, Kathleen A.; Mariotto, Angela.

In: Statistical methods in medical research, Vol. 13, No. 6, 01.12.2004, p. 421-442.

Research output: Contribution to journalArticle

Feuer, Eric J. ; Etzioni, Ruth ; Cronin, Kathleen A. ; Mariotto, Angela. / The use of modeling to understand the impact of screening on US mortality : Examples from mammography and PSA testing. In: Statistical methods in medical research. 2004 ; Vol. 13, No. 6. pp. 421-442.
@article{ccd55c9d881d4d84bb76eb53ec232b88,
title = "The use of modeling to understand the impact of screening on US mortality: Examples from mammography and PSA testing",
abstract = "Surveillance data represent a vital resource for understanding the impact of cancer control interventions on the population cancer burden. However, population cancer trends are a complex product of many factors, and estimating the contribution of any one of these factors can be challenging. Surveillance modeling is a technique for estimating the contribution of one or more interventions of interest to trends in disease incidence and mortality. In this article, we present several approaches to surveillance modeling of cancer screening interventions. We classify models as biological or epidemiological, depending on whether they model the full unobservable aspects of disease onset and progression, or models which reduce the complex process to simpler terms by summarizing portions of the disease process using mostly observed population level measures. We also describe differences between macrolevel models, microsimulation models and mechanistic models. We discuss procedures for model calibration and validation, and methods for presenting model results which are robust with respect to certain types of biased model estimates. As examples, we present several models of the impact of mammography screening on breast cancer mortality, and PSA screening on prostate cancer mortality. Both these examples are appropriate uses of surveillance modeling, even though for mammography there is extensive (although somewhat controversial) randomized trial evidence, whereas for PSA this biomarker has seen extensive use as a screening test prior to any controlled trial evidence of its efficacy. Some of the models presented here were developed as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network.",
author = "Feuer, {Eric J.} and Ruth Etzioni and Cronin, {Kathleen A.} and Angela Mariotto",
year = "2004",
month = "12",
day = "1",
doi = "10.1191/0962280204sm376ra",
language = "English (US)",
volume = "13",
pages = "421--442",
journal = "Statistical Methods in Medical Research",
issn = "0962-2802",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - The use of modeling to understand the impact of screening on US mortality

T2 - Examples from mammography and PSA testing

AU - Feuer, Eric J.

AU - Etzioni, Ruth

AU - Cronin, Kathleen A.

AU - Mariotto, Angela

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Surveillance data represent a vital resource for understanding the impact of cancer control interventions on the population cancer burden. However, population cancer trends are a complex product of many factors, and estimating the contribution of any one of these factors can be challenging. Surveillance modeling is a technique for estimating the contribution of one or more interventions of interest to trends in disease incidence and mortality. In this article, we present several approaches to surveillance modeling of cancer screening interventions. We classify models as biological or epidemiological, depending on whether they model the full unobservable aspects of disease onset and progression, or models which reduce the complex process to simpler terms by summarizing portions of the disease process using mostly observed population level measures. We also describe differences between macrolevel models, microsimulation models and mechanistic models. We discuss procedures for model calibration and validation, and methods for presenting model results which are robust with respect to certain types of biased model estimates. As examples, we present several models of the impact of mammography screening on breast cancer mortality, and PSA screening on prostate cancer mortality. Both these examples are appropriate uses of surveillance modeling, even though for mammography there is extensive (although somewhat controversial) randomized trial evidence, whereas for PSA this biomarker has seen extensive use as a screening test prior to any controlled trial evidence of its efficacy. Some of the models presented here were developed as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network.

AB - Surveillance data represent a vital resource for understanding the impact of cancer control interventions on the population cancer burden. However, population cancer trends are a complex product of many factors, and estimating the contribution of any one of these factors can be challenging. Surveillance modeling is a technique for estimating the contribution of one or more interventions of interest to trends in disease incidence and mortality. In this article, we present several approaches to surveillance modeling of cancer screening interventions. We classify models as biological or epidemiological, depending on whether they model the full unobservable aspects of disease onset and progression, or models which reduce the complex process to simpler terms by summarizing portions of the disease process using mostly observed population level measures. We also describe differences between macrolevel models, microsimulation models and mechanistic models. We discuss procedures for model calibration and validation, and methods for presenting model results which are robust with respect to certain types of biased model estimates. As examples, we present several models of the impact of mammography screening on breast cancer mortality, and PSA screening on prostate cancer mortality. Both these examples are appropriate uses of surveillance modeling, even though for mammography there is extensive (although somewhat controversial) randomized trial evidence, whereas for PSA this biomarker has seen extensive use as a screening test prior to any controlled trial evidence of its efficacy. Some of the models presented here were developed as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network.

UR - http://www.scopus.com/inward/record.url?scp=9444271756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444271756&partnerID=8YFLogxK

U2 - 10.1191/0962280204sm376ra

DO - 10.1191/0962280204sm376ra

M3 - Article

C2 - 15587432

AN - SCOPUS:9444271756

VL - 13

SP - 421

EP - 442

JO - Statistical Methods in Medical Research

JF - Statistical Methods in Medical Research

SN - 0962-2802

IS - 6

ER -